Randomized Phase III SIERRA Trial of 131 I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka GyurkoczaRajneesh NathStuart SeropianHannah K ChoeMark R LitzowCamille N AbboudNebu KoshyPatrick Joseph StiffBenjamin K TomlinsonSunil AbhyankarJames M ForanParameswaran N HariGeorge ChenZaid Al-KadhimiPartow KebriaeiMitchell SabloffJohnnie J OrozcoKatarzyna JamiesonMargarida SilvermanKoen van BesienMichael SchusterArjun Datt LawKarilyn T M LarkinNeeta Pandit-TaskarScott Douglas RowleyPashna MunshiRachel CookMoshe Y LevyHillard M LazarusBrenda M SandmaierJohn M PagelVijay ReddyJames MacDougallKathleen McNamaraJennifer SprossElaina HaeuberMadhuri VusirikalaAkash NaharAvinash DesaiSergio A GiraltPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
I-apamistamab was well tolerated and could address an unmet need in this population.
Keyphrases
- phase iii
- acute myeloid leukemia
- open label
- double blind
- stem cell transplantation
- clinical trial
- placebo controlled
- phase ii
- acute lymphoblastic leukemia
- healthcare
- palliative care
- bone marrow
- allogeneic hematopoietic stem cell transplantation
- multiple myeloma
- hodgkin lymphoma
- quality improvement
- diffuse large b cell lymphoma
- hematopoietic stem cell
- pain management
- study protocol
- randomized controlled trial
- high dose
- affordable care act
- chronic pain